Consensus Shanghai Junshi Biosciences Co., Ltd.

Equities

Market Closed - Hong Kong S.E. Other stock markets 04:08:22 2024-05-10 am EDT			5-day change	1st Jan Change
12.62 ^HKD	-2.77%		-1.56%	-35.08%

Apr. 29	Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 25	Shanghai Junshi Biosciences Receives Hong Kong Approval for Cancer Drug Toripalimab	MT

ad2314.hZtkjUZCuNWY1BV763PgcgwLMPPLMSCeZkkckDTWeBg.0_Zd2Qct3bvC43ITuhSwM2dlRr-4dnPZL3lE_Xe4PHrBww31BzL5sNCtdg~3106d5c53ed816c1487261e0361d343d

Shanghai Junshi Biosciences' 2022 Loss Widens, Misses Analysts' Expectations	23-02-28	MT
UBS Adjusts Shanghai Junshi Biosciences' Price Target to HK$65.40 From HK$70.90, Keeps at Buy	22-09-05	MT
UBS Adjusts Shanghai Junshi Biosciences’ Price Target to HK$70.90 From HK$77.70, Keeps at Buy	22-05-26	MT

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

11.67 CNY

Average target price

22.81 CNY

Spread / Average Target

+95.50%

High Price Target

42.1 CNY

Spread / Highest target

+260.73%

Low Price Target

11.12 CNY

Spread / Lowest Target

-4.74%

UBS

Trading Rating

Investor Rating

ESG Refinitiv

C+